ADAR1 levels in rectal adenocarcinoma
The Effect of ADAR1 Expression Level on Total Neoadjuvant Treatment Response in Locally Advanced Rectal Cancer
For people with locally advanced rectal adenocarcinoma getting total neoadjuvant therapy, clinicians will measure ADAR1 levels to see if they relate to how the tumor responds.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Necmettin Erbakan University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Konya, Meram) |
| Trial ID | NCT07108348 on ClinicalTrials.gov |
What this trial studies
This is an observational study measuring ADAR1 (adenosine deaminase acting on RNA1) expression in tumor tissue from patients with local or locally advanced rectal adenocarcinoma treated with total neoadjuvant therapy (TNT). Tumor staging and response will be documented using colonoscopy and pelvic MRI, and ADAR1 levels will be correlated with clinical and radiologic response and treatment decisions (surgery versus watch-and-wait). Eligible participants are ECOG 0–2, have no metastatic disease, and have no contraindications to chemotherapy or radiotherapy. The study is conducted at Necmettin Erbakan University with collaboration from the Turkish Society of Medical Oncology.
Who should consider this trial
Good fit: Adults with histologically confirmed local or locally advanced rectal adenocarcinoma, ECOG 0–2, planned for TNT, and willing to provide informed consent and tissue samples are the ideal candidates.
Not a fit: Patients with metastatic disease, a second primary cancer, contraindications to chemo/radiation, or those who do not provide consent or tissue samples are unlikely to benefit from the study findings.
Why it matters
Potential benefit: If successful, ADAR1 measurement could help predict who will respond to TNT and support decisions about avoiding surgery or choosing sphincter-sparing approaches.
How similar studies have performed: ADAR1 has been linked to tumor behavior in other cancer types, but its value as a predictive biomarker for TNT response in rectal cancer has not been firmly established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological and staging diagnosis of local/locally advanced rectal cancer * ECOG performance score between 0 and 2 * No contraindications for chemotherapy (CT) and/or radiotherapy (RT) Exclusion Criteria: * Those diagnosed with metastatic rectal cancer * Those suspected of having rectal cancer or patients with a diagnosis of a second primary cancer * Those who have not signed the informed consent form * Those with contraindications for chemotherapy (CT) and/or radiation therapy (RT)
Where this trial is running
Konya, Meram
- Necmettin Erbakan University Faculty of Medicine, Departmen of Medical Oncology — Konya, Meram, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Ahmet Oruç, MD
- Email: mdahmetoruc@gmail.com
- Phone: +90 0505 704 50 20
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.